TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?

ABSTRACT: Treatment-free remission (TFR) is a new and significant goal of chronic myeloid leukemia management. TFR should be considered for patients in stable deep molecular response (DMR) after careful discussion in the shared decision-making process. Second-generation tyrosine kinase inhibitors (TKIs) improve the speed of response and the incidence of DMR. Treatment may be changed to a more active TKI to improve the depth of response in selected patients who have not reached DMR. Stem cell persistence is associated with active immune surveillance and activation of BCR-ABL1-independent pathways, eg, STAT3, JAK1/2, and BCL2. Ongoing studies aim to prove the efficacy of maintenance therapies targeting these pathways after TKI discontinuation.

SUBMITTER: Hochhaus A 

PROVIDER: S-EPMC8791110 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature